
Opinion|Videos|April 3, 2025
Discussing ADC Risks, Benefits, and Regimens With Patients
Panelists discuss how health care professionals use clear, tailored communication to explain antibody-drug conjugate (ADC) risks, benefits, and regimens. They provide education, address concerns, and ensure adherence through counseling and shared decision-making.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- At your institution, how do you effectively communicate with patients about ADC therapies (eg, risks, benefits, treatment regimens)?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2
2
Current and Emerging BCMAxCD3 Bispecifics
3
Biosimilar Stivant Shows Noninferior Efficacy and Comparable Safety to Reference Bevacizumab
4
Evolocumab Reduces Risk of Major Events in Patients Without Prior Cardiovascular History
5